<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806390</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00040965</org_study_id>
    <nct_id>NCT00806390</nct_id>
  </id_info>
  <brief_title>Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol</brief_title>
  <official_title>GCC0766: Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate whether giving prophylactic metoprolol
      prior to and during anthracycline or trastuzumab therapy will decrease the incidence of
      anthracycline-induced cardiomyopathy. Patients are randomized to receive metoprolol or no
      treatment prior to anthracycline or trastuzumab treatment. The ejection fraction, as measured
      by nuclear ventriculography is measured before and after treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled exploration. Consent will be obtained from patients
      receiving care for cancer with anthracycline or trastuzumab at the University Of Maryland
      Greenebaum Cancer Center prior to initiation of anthracycline or trastuzumab treatment during
      the initial oncology visit.

      Patients will be evaluated in the initial consultation in the oncology clinic during which
      time consent will be obtained, and any patient with bradycardia (HR less than 50) or other
      contraindication will be excluded from the study. The patients will be randomly assigned to
      metoprolol vs. control groups during this initial visit. Individuals in the control group
      will not receive any study drug where as those in the metoprolol group will be given
      prophylactic metoprolol prior to initiation of anthracycline or trastuzumab treatment.
      Metoprolol tartrate will be provided to each patient randomized to the metoprolol group.

      Also at the time of the initial consultation, a baseline MUGA will be obtained for evaluation
      of left ventricular ejection fraction. Additionally, a post-treatment MUGA will be obtained
      after the final course of chemotherapy. Lastly, also at the initial visit, one vial of blood
      will be obtained from each patient to test for genetic polymorphisms, as described in the
      background section, which may contribute to the response to beta blockade in the prevention
      of anthracycline or trastuzumab induced cardiomyopathy.

      Each participant in the metoprolol group will be started on 25 mg of metoprolol tartrate
      twice a day prior to initiation of the anthracycline or trastuzumab. After one week, this
      dose will be increased to 50 mg twice daily, if tolerated. Prior to increasing the dose, the
      patients will be seen in the cardiology research clinic by the study doctor and evaluated for
      side effects. After another week the dose will again be increased to 100 mg twice daily. The
      dose can be decreased at any time if side effects occur such as bradycardia with HR less than
      50 or hypotension with SBP less than 90. The beta blocker will be held for two days prior to
      the post-treatment MUGA so as not to acutely affect heart rate, as a decrease in heart rate
      would be expected to increase EF14. Abrupt cessation of metoprolol tartrate will not lead to
      withdrawal of beta-blockade. This study will end with the post-treatment MUGA. The primary
      end point of this study will be the change in EF before and after anthracycline or
      trastuzumab treatment. A pill diary will be maintained to document compliance of study
      medication.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ejection Fraction by MUGA</measure>
    <time_frame>Pre and post anthracycline treatment</time_frame>
    <description>Because of the inability to enroll an adequate number of patients, (only 15 out of a planned 50) no data analysis was collected or performed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receiving metoprolol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Not receiving metoprolol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Metroprolol tartrate titrated up</description>
    <arm_group_label>Metoprolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have confirmed malignancy for which standard regimens of anthracyclines
             or trastuzumab are being offered as treatment at the University of Maryland Greenebaum
             Cancer Center. Patients must either receive 4 cycles of anthracycline for a total dose
             of 240 mg/m2 or six cycles of TAC for a total dose of 300 mg/m2 or trastuzumab.

          2. Age &gt; 18 years

          3. Ability to understand and willingness to sign a written informed consent document.

          4. Women of childbearing potential may participate in this study only if they have a
             negative pregnancy test and agree not to become pregnant during the study. Woman of
             childbearing potential must use an effective method of birth control such as hormonal
             contraceptives (oral and implant) condoms, diaphragms, spermicidal foam or jelly,
             surgical (hysterectomy or tubal ligation) or intrauterine device.

        Exclusion Criteria:

          1. Patients who have established dilated or restrictive cardiomyopathy with EF &lt; 40 %.

          2. Patients with severe mitral or aortic valve disease (valve area &lt;1cm squared).

          3. Patients who have any contraindication to metoprolol, in particular bradycardia with
             HR &lt; 50, or severe reactive pulmonary disease such as asthma. Patients who take
             mibefradil or psychiatric drugs (such as phenothiazines including chlorpromazine and
             thioridazine) will also be excluded from the study as they have serious interactions
             with beta-blockers

          4. Patients who have untreated thyroid function disorder.

          5. Pregnant and nursing women are excluded from this study because of potential risk for
             adverse events to the fetus.

          6. Patients with any impediment to swallowing tablets would be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen S Gottlieb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2008</study_first_submitted>
  <study_first_submitted_qc>December 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2008</study_first_posted>
  <results_first_submitted>May 19, 2014</results_first_submitted>
  <results_first_submitted_qc>June 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2014</results_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Steve Gottlieb</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ejection fraction</keyword>
  <keyword>anthracyclines</keyword>
  <keyword>beta-adrenergic blockade</keyword>
  <keyword>Patients receiving anthracyclines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metoprolol</title>
          <description>Receiving metoprolol
Metoprolol: Metroprolol tartrate titrated up</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Not receiving metoprolol</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metoprolol</title>
          <description>Receiving metoprolol
Metoprolol: Metroprolol tartrate titrated up</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Not receiving metoprolol</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="11"/>
                    <measurement group_id="B2" value="47" spread="8"/>
                    <measurement group_id="B3" value="49" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ejection Fraction by MUGA</title>
        <description>Because of the inability to enroll an adequate number of patients, (only 15 out of a planned 50) no data analysis was collected or performed.</description>
        <time_frame>Pre and post anthracycline treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoprolol</title>
            <description>Receiving metoprolol
Metoprolol: Metroprolol tartrate titrated up</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Not receiving metoprolol</description>
          </group>
        </group_list>
        <measure>
          <title>Ejection Fraction by MUGA</title>
          <description>Because of the inability to enroll an adequate number of patients, (only 15 out of a planned 50) no data analysis was collected or performed.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Metoprolol</title>
          <description>Receiving metoprolol
Metoprolol: Metroprolol tartrate titrated up</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Not receiving metoprolol</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephen Gottlieb</name_or_title>
      <organization>UMaryland</organization>
      <phone>410-328-8788</phone>
      <email>sgottlie@medicine.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

